RU2016110874A - Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний - Google Patents

Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний Download PDF

Info

Publication number
RU2016110874A
RU2016110874A RU2016110874A RU2016110874A RU2016110874A RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A RU2016110874 A RU 2016110874A
Authority
RU
Russia
Prior art keywords
cancer
inhibitor
alk
combination according
combination
Prior art date
Application number
RU2016110874A
Other languages
English (en)
Russian (ru)
Other versions
RU2016110874A3 (enExample
Inventor
Дженнифер Лесли ХАРРИС
Наньсинь Ли
Тимоти Р. СМИТ
Яэл МОСС
Эндрю ВУД
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2016110874A publication Critical patent/RU2016110874A/ru
Publication of RU2016110874A3 publication Critical patent/RU2016110874A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016110874A 2013-08-28 2014-08-28 Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний RU2016110874A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
US61/871,275 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (2)

Publication Number Publication Date
RU2016110874A true RU2016110874A (ru) 2017-10-04
RU2016110874A3 RU2016110874A3 (enExample) 2018-06-27

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016110874A RU2016110874A (ru) 2013-08-28 2014-08-28 Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний

Country Status (12)

Country Link
US (2) US20160361314A1 (enExample)
EP (1) EP3038652B1 (enExample)
JP (1) JP6479812B2 (enExample)
KR (1) KR20160047521A (enExample)
CN (1) CN106029099A (enExample)
AU (3) AU2014312261A1 (enExample)
BR (1) BR112016004358A8 (enExample)
CA (1) CA2922684A1 (enExample)
ES (1) ES2674361T3 (enExample)
MX (1) MX2016002580A (enExample)
RU (1) RU2016110874A (enExample)
WO (1) WO2015031666A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835886C1 (ru) * 2019-09-05 2025-03-05 Клиникум Рехтс Дер Изар Дер Технишен Универзитет Мюнхен Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11208630B2 (en) * 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
ES3055186T3 (en) * 2019-04-04 2026-02-10 Dana Farber Cancer Inst Inc Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
JP7642556B2 (ja) 2019-11-18 2025-03-10 中外製薬株式会社 併用医薬
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
EP3025724B1 (en) * 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
PT2670401E (pt) * 2011-02-02 2015-10-12 Novartis Ag Métodos de utilização de inibidores de alk

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835886C1 (ru) * 2019-09-05 2025-03-05 Клиникум Рехтс Дер Изар Дер Технишен Универзитет Мюнхен Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента

Also Published As

Publication number Publication date
AU2017219093A1 (en) 2017-09-14
AU2014312261A1 (en) 2016-03-10
US20180318305A1 (en) 2018-11-08
RU2016110874A3 (enExample) 2018-06-27
EP3038652B1 (en) 2018-03-21
JP2016529285A (ja) 2016-09-23
BR112016004358A8 (pt) 2020-02-11
WO2015031666A1 (en) 2015-03-05
AU2018236813A1 (en) 2018-10-18
CA2922684A1 (en) 2015-03-05
JP6479812B2 (ja) 2019-03-06
ES2674361T3 (es) 2018-06-29
CN106029099A (zh) 2016-10-12
US20160361314A1 (en) 2016-12-15
MX2016002580A (es) 2016-10-26
KR20160047521A (ko) 2016-05-02
EP3038652A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
CA2922684A1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
JP2016501221A5 (enExample)
TR201807411T4 (tr) DNA-PK inhibitörleri.
RU2015125307A (ru) Комбинированная терапия
JP2016533366A5 (enExample)
JP2015520753A5 (enExample)
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
JP2018512391A5 (enExample)
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
JP2017530950A5 (enExample)
EA201790122A1 (ru) Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
JP2015536964A5 (enExample)
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
JP2015508103A5 (enExample)
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
JP2014097929A5 (enExample)
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ
JP2015523397A5 (enExample)
MX380928B (es) Inhibidores de kras g12c.
JP2011515397A5 (enExample)
JP2017514806A5 (enExample)
RU2017115773A (ru) 17альфа-бензоат кортексолона для применения в лечении опухолей

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20200415